-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $20

Benzinga·03/17/2025 11:48:48
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $32 to $20.